Targeting hypoxia cell signaling for cancer therapy
10.1007/s10555-007-9059-x
Crossref journal-article
Springer Science and Business Media LLC
Cancer and Metastasis Reviews (297)
Authors 1
  1. Giovanni Melillo (first)
References 111 Referenced 181
  1. Harris, A. L. (2002). Hypoxia—A key regulatory factor in tumour growth. Nature Reviews. Cancer, 2, 38–47. (10.1038/nrc704) / Nature Reviews. Cancer by A. L. Harris (2002)
  2. Brown, J. M, & Wilson, W. R. (2004). Exploiting tumour hypoxia in cancer treatment. Nature Reviews. Cancer, 4, 437–447. (10.1038/nrc1367) / Nature Reviews. Cancer by J. M Brown (2004)
  3. Melillo, G. (2006). Inhibiting hypoxia-inducible factor 1 for cancer therapy. Molecular Cancer Research, 4, 601–605. (10.1158/1541-7786.MCR-06-0235) / Molecular Cancer Research by G. Melillo (2006)
  4. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nature Reviews. Cancer, 3, 721–732. (10.1038/nrc1187) / Nature Reviews. Cancer by G. L. Semenza (2003)
  5. Giaccia, A., Siim, B. G., & Johnson, R. S. (2003). HIF-1 as a target for drug development. Nature Reviews. Drug Discovery, 2, 803–811. (10.1038/nrd1199) / Nature Reviws. Drug Discovery by A. Giaccia (2003)
  6. Maxwell, P. H. (2005). The HIF pathway in cancer. Seminars in Cell & Developmental Biology, 16, 523–530. (10.1016/j.semcdb.2005.03.001) / Seminars in Cell & Developmental Biology by P. H. Maxwell (2005)
  7. Melillo, G. (2004). HIF-1: A target for cancer, ischemia and inflammation—Too good to be true? Cell Cycle, 3, 154–155. (10.4161/cc.3.2.689) / Cell Cycle by G. Melillo (2004)
  8. Kaufman, B., Scharf, O., Arbeit, J., Ashcroft, M., Brown, J. M., Bruick, R. K., et al. (2004). Proceedings of the oxygen homeostasis/hypoxia meeting. Cancer Research, 64, 3350–3356. (10.1158/0008-5472.CAN-03-2611) / Cancer Research by B. Kaufman (2004)
  9. Melillo, G., & Semenza, G. L. (2006). Meeting report: Exploiting the tumor microenvironment for therapeutics. Cancer Research, 66, 4558–4560. (10.1158/0008-5472.CAN-06-0069) / Cancer Research by G. Melillo (2006)
  10. Sun, X., Kanwar, J. R., Leung, E., Lehnert, K., Wang, D., & Krissansen, G. W. (2001). Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. Gene Therapy, 8, 638–645. (10.1038/sj.gt.3301388) / Gene Therapy by X. Sun (2001)
  11. Zhang, X., Kon, T., Wang, H., Li, F., Huang, Q., Rabbani, Z. N., et al. (2004). Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Research, 64, 8139–8142. (10.1158/0008-5472.CAN-03-2301) / Cancer Research by X. Zhang (2004)
  12. Chang, Q., Qin, R., Huang, T., Gao, J., & Feng, Y. (2006). Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas, 32, 297–305. (10.1097/00006676-200604000-00010) / Pancreas by Q. Chang (2006)
  13. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S. W., et al. (2005). Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Research, 65, 7249–7258. (10.1158/0008-5472.CAN-04-4426) / Cancer Research by L. Li (2005)
  14. Dachs, G. U., Patterson, A. V., Firth, J. D., Ratcliffe, P. J., Townsend, K. M., Stratford, I. J., et al. (1997). Targeting gene expression to hypoxic tumor cells. Nature Medicine, 3, 515–520. (10.1038/nm0597-515) / Natural Medicines by G. U. Dachs (1997)
  15. Cuevas, Y., Hernandez-Alcoceba, R., Aragones, J., Naranjo-Suarez, S., Castellanos, M. C., Esteban, M. A., et al. (2003). Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Research, 63, 6877–6884. / Cancer Research by Y. Cuevas (2003)
  16. Brown, J. M. (1993). SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. British Journal of Cancer, 67, 1163–1170. (10.1038/bjc.1993.220) / British Journal of Cancer by J. M. Brown (1993)
  17. Peters, K. B., & Brown, J. M. (2002). Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Research, 62, 5248–5253. / Cancer Research by K. B. Peters (2002)
  18. von Pawel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., et al. (2000). Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. Journal of Clinical Oncology, 18, 1351–1359. (10.1200/JCO.2000.18.6.1351) / Journal of Clinical Oncology by J. Pawel von (2000)
  19. Williamson, S. K., Crowley, J. J., Lara, P. N., Jr., McCoy, J., Lau, D. H., Tucker, R. W., et al. (2005). Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. Journal of Clinical Oncology, 23, 9097–9104. (10.1200/JCO.2005.01.3771) / Journal of Clinical Oncology by S. K. Williamson (2005)
  20. Rischin, D., Peters, L., Fisher, R., Macann, A., Denham, J., Poulsen, M., et al. (2005). Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). Journal of Clinical Oncology, 23, 79–87. (10.1200/JCO.2005.01.072) / Journal of Clinical Oncology by D. Rischin (2005)
  21. Lemmon, M. J., van Zijl, P., Fox, M. E., Mauchline, M. L., Giaccia, A. J., Minton, N. P., et al. (1997). Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Therapy, 4, 791–796. (10.1038/sj.gt.3300468) / Gene Therapy by M. J. Lemmon (1997)
  22. Liu, S. C., Minton, N. P., Giaccia, A. J., & Brown, J. M. (2002). Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy, 9, 291–296. (10.1038/sj.gt.3301659) / Gene Therapy by S. C. Liu (2002)
  23. Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001). Combination bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National Academy of Sciences of the United States of America, 98, 15155–15160. (10.1073/pnas.251543698) / Proceedings of the National Academy of Sciences of the United States of America by L. H. Dang (2001)
  24. Cheong, I., Huang, X., Bettegowda, C., Diaz, L. A., Jr., Kinzler, K. W., Zhou, S., et al. (2006). A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science, 314, 1308–1311. (10.1126/science.1130651) / Science by I. Cheong (2006)
  25. Schioppa, T., Uranchimeg, B., Saccani, A., Biswas, S. K., Doni, A., Rapisarda, A., et al. (2003). Regulation of the chemokine receptor CXCR4 by hypoxia. Journal of Experimental Medicine, 198, 1391–1402. (10.1084/jem.20030267) / Journal of Experimental Medicine by T. Schioppa (2003)
  26. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003). Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 3, 347–361. (10.1016/S1535-6108(03)00085-0) / Cancer Cell by S. Pennacchietti (2003)
  27. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q. T., et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440, 1222–1226. (10.1038/nature04695) / Nature by J. T. Erler (2006)
  28. Ferrara, N. (2005). VEGF as a therapeutic target in cancer. Oncology, 69(Suppl 3), 11–16. (10.1159/000088479) / Oncology by N. Ferrara (2005)
  29. Park, E. J., Kong, D., Fisher, R., Cardellina, J., Shoemaker, R. H., & Melillo, G. (2006). Targeting the PAS-a domain of HIF-1alpha for development of small molecule inhibitors of HIF-1. Cell Cycle, 5(16), 1847–1853. (10.4161/cc.5.16.3019) / Cell Cycle by E.J. Park (2006)
  30. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., et al. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. Genes & Development, 14, 391–396. (10.1101/gad.14.4.391) / Genes & Development by W. Zundel (2000)
  31. Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine, 10, 594–601. (10.1038/nm1052) / Natural Medicines by P. K. Majumder (2004)
  32. Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., et al. (2006). Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine, 12, 2–127. / Natural Medicines by G. V. Thomas (2006)
  33. Del Bufalo, D., Ciuffreda, L., Trisciuoglio, D., Desideri, M., Cognetti, F., Zupi, G., et al. (2006). Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Research, 66, 5549–5554. (10.1158/0008-5472.CAN-05-2825) / Cancer Research by D. Bufalo Del (2006)
  34. Calvani, M., Rapisarda, A., Uranchimeg, B., Shoemaker, R. H., & Melillo, G. (2005). Hypoxic induction of a HIF-1{alpha}-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood, 107, 2705–2712. (10.1182/blood-2005-09-3541) / Blood by M. Calvani (2005)
  35. Wan, X., Shen, N., Mendoza, A., Khanna, C., & Helman, L. J. (2006). CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia, 8, 394–401. (10.1593/neo.05820) / Neoplasia by X. Wan (2006)
  36. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., et al. (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Research, 60, 1541–1545. / Cancer Research by H. Zhong (2000)
  37. Pore, N., Jiang, Z., Gupta, A., Cerniglia, G., Kao, G. D., & Maity, A. (2006). EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Research, 66, 3197–3204. (10.1158/0008-5472.CAN-05-3090) / Cancer Research by N. Pore (2006)
  38. Peng, X., Karna, P., Cao, Z., Jiang, B., Zhou, M., & Yang, L. (2006). Cross-talk between epidermal growth factor receptor and HIF-1 signal pathways increases resistance to apoptosis by upregulating survivin gene expression. Journal of Biological Chemistry 281, 25903–25914. (10.1074/jbc.M603414200)
  39. Luwor, R. B., Lu, Y., Li, X., Mendelsohn, J., & Fan, Z. (2005). The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene, 24, 4433–4441. (10.1038/sj.onc.1208625) / Oncogene by R. B. Luwor (2005)
  40. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001). HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology, 21, 3995–4004. (10.1128/MCB.21.12.3995-4004.2001) / Molecular and Cellular Biology by E. Laughner (2001)
  41. Koukourakis, M. I., Simopoulos, C., Polychronidis, A., Perente, S., Botaitis, S., Giatromanolaki, A., et al. (2003). The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: Dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Anticancer Research, 23, 1673–1680. / Anticancer Research by M. I. Koukourakis (2003)
  42. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D., & Sillaber, C. (2002). BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 100, 3767–3775. (10.1182/blood-2002-01-0109) / Blood by M. Mayerhofer (2002)
  43. Litz, J., & Krystal, G. W. (2006). Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Molecular Cancer Therapy, 5, 1415–1422. (10.1158/1535-7163.MCT-05-0503) / Molecular Cancer Therapy by J. Litz (2006)
  44. Cao, Z., Fang, J., Xia, C., Shi, X., & Jiang, B. H. (2004). trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clinical Cancer Research, 10, 5253–5263. (10.1158/1078-0432.CCR-03-0588) / Clinical Cancer Research by Z. Cao (2004)
  45. Fang, J., Cao, Z., Chen, Y. C., Reed, E., & Jiang, B. H. (2004). 9-beta-D-arabinofuranosyl-2-fluoroadenine inhibits expression of vascular endothelial growth factor through hypoxia-inducible factor-1 in human ovarian cancer cells. Molecular Pharmacology, 66, 178–186. (10.1124/mol.66.1.178) / Molecular Pharmacology by J. Fang (2004)
  46. Fang, J., Xia, C., Cao, Z., Zheng, J. Z., Reed, E., & Jiang, B. H. (2005). Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB Journal, 19, 342–353. (10.1096/fj.04-2175com) / FASEB Journal by J. Fang (2005)
  47. Pore, N., Gupta, A. K., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. et al. (2006). Nelfinavir down-regulates hypoxia-inducible factor 1{alpha} and VEGF expression and increases tumor oxygenation: Implications for radiotherapy. Cancer Research, 66, 9252–9259. (10.1158/0008-5472.CAN-06-1239) / Cancer Research by N. Pore (2006)
  48. Tan, C., de Noronha, R. G., Roecker, A. J., Pyrzynska, B., Khwaja, F., Zhang, Z., et al. (2005). Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Research, 65, 605–612. (10.1158/0008-5472.605.65.2) / Cancer Research by C. Tan (2005)
  49. Zhang, Q., Tang, X., Lu, Q., Zhang, Z., Rao, J., & Le, A. D. (2006). Green tea extract and (−)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Molecular Cancer Therapy, 5, 1227–1238. (10.1158/1535-7163.MCT-05-0490) / Molecular Cancer Therapy by Q. Zhang (2006)
  50. Zhang, Q., Tang, X., Lu, Q. Y., Zhang, Z. F., Brown, J., & Le, A. D. (2005). Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Molecular Cancer Therapy, 4, 1465–1474. (10.1158/1535-7163.MCT-05-0198) / Molecular Cancer Therapy by Q. Zhang (2005)
  51. Zhong, X. S., Zheng, J. Z., Reed, E., & Jiang, B. H. (2004). SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochemical and Biophysical Research Communications, 324, 471–480. (10.1016/j.bbrc.2004.09.082) / Biochemical and Biophysical Research Communications by X. S. Zhong (2004)
  52. Pommier, Y. (2006). Topoisomerase I inhibitors: Camptothecins and beyond. Nature Reviews Cancer, 6, 789–802. (10.1038/nrc1977) / Nature Reviews. Cancer by Y. Pommier (2006)
  53. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H., et al. (2002). Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Research, 62, 4316–4324. / Cancer Research by A. Rapisarda (2002)
  54. Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004). Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Research, 64, 1475–1482. (10.1158/0008-5472.CAN-03-3139) / Cancer Research by A. Rapisarda (2004)
  55. Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., et al. (2004). Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Research, 64, 6845–6848. (10.1158/0008-5472.CAN-04-2116) / Cancer Research by A. Rapisarda (2004)
  56. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S. P., et al. (2003). 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 3, 363–375. (10.1016/S1535-6108(03)00077-1) / Cancer Cell by N. J. Mabjeesh (2003)
  57. Escuin, D., Kline, E. R., & Giannakakou, P. (2005). Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Research, 65, 9021–9028. (10.1158/0008-5472.CAN-04-4095) / Cancer Research by D. Escuin (2005)
  58. Jung, Y. J., Isaacs, J. S., Lee, S., Trepel, J., & Neckers, L. (2003). Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. Journal of Biological Chemistry, 278, 7445–7452. (10.1074/jbc.M209804200) / Journal of Biological Chemistry by Y. J. Jung (2003)
  59. Kang, S. H., Cho, H. T., Devi, S., Zhang, Z., Escuin, D., Liang, Z., et al. (2006). Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Research, 66, 11991–11997. (10.1158/0008-5472.CAN-06-1320) / Cancer Research by S. H. Kang (2006)
  60. Ricker, J. L., Chen, Z., Yang, X. P., Pribluda, V. S., Swartz, G. M., & Van Waes, C. (2004). 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clinical Cancer Research, 10, 8665–8673. (10.1158/1078-0432.CCR-04-1393) / Clinical Cancer Research by J. L. Ricker (2004)
  61. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002). Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. Journal of Biological Chemistry, 277, 29936–29944. (10.1074/jbc.M204733200) / Journal of Biological Chemistry by J. S. Isaacs (2002)
  62. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., et al. (2002). Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Research, 62, 2478–2482. / Cancer Research by N. J. Mabjeesh (2002)
  63. Hur, E., Kim, H. H., Choi, S. M., Kim, J. H., Yim, S., Kwon, H. J., et al. (2002). Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Molecular Pharmacology, 62, 975–982. (10.1124/mol.62.5.975) / Molecular Pharmacology by E. Hur (2002)
  64. Kurebayashi, J., Otsuki, T., Kurosumi, M., Soga, S., Akinaga, S., & Sonoo, H. (2001). A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts. Japanese Journal of Cancer Research, 92, 1342–1351. (10.1111/j.1349-7006.2001.tb02159.x) / Japanese Journal of Cancer Research by J. Kurebayashi (2001)
  65. Han, J. Y., Oh, S. H., Morgillo, F., Myers, J. N., Kim, E., Hong, W. K., et al. (2005). Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. Journal of the National Cancer Institute, 97, 1272–1286. (10.1093/jnci/dji251) / Journal of the National Cancer Institute by J. Y. Han (2005)
  66. Osada, M., Imaoka, S., & Funae, Y. (2004). Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Letters, 575, 59–63. (10.1016/j.febslet.2004.08.036) / FEBS Letters by M. Osada (2004)
  67. Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J. E., Lee, S. W., et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine, 7, 437–443. (10.1038/86507) / Natural Medicines by M. S. Kim (2001)
  68. Fath, D. M., Kong, X., Liang, D., Lin, Z., Chou, A., Jiang, Y., et al. (2006). Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. Journal of Biological Chemistry, 281, 13612–13619. (10.1074/jbc.M600456200) / Journal of Biological Chemistry by D. M. Fath (2006)
  69. Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Molecular and Cellular Biology, 26, 2019–2028. (10.1128/MCB.26.6.2019-2028.2006) / Molecular and Cellular Biology by X. Kong (2006)
  70. Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., et al. (2006). Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1{alpha}. Cancer Research, 66, 8814–8821. (10.1158/0008-5472.CAN-05-4598) / Cancer Research by D. Z. Qian (2006)
  71. Chun, Y. S., Yeo, E. J., & Park, J. W. (2004). Versatile pharmacological actions of YC-1: Anti-platelet to anticancer. Cancer Letters, 207, 1–7. (10.1016/j.canlet.2004.01.005) / Cancer Letters by Y. S. Chun (2004)
  72. Chun, Y. S., Yeo, E. J., Choi, E., Teng, C. M., Bae, J. M., Kim, M. S., et al. (2001). Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochemical Pharmacology, 61, 947–954. (10.1016/S0006-2952(01)00564-0) / Biochemical Pharmacology by Y. S. Chun (2001)
  73. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., et al. (2003). YC-1: A potential anticancer drug targeting hypoxia-inducible factor 1. Journal of the National Cancer Institute, 95, 516–525. (10.1093/jnci/95.7.516) / Journal of the National Cancer Institute by E. J. Yeo (2003)
  74. Kim, H. L., Yeo, E. J., Chun, Y. S., & Park, J. W. (2006). A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. International Journal of Oncology, 29, 255–260. / International Journal of Oncology by H. L. Kim (2006)
  75. Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004). Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Molecular Cancer Therapy, 3, 233–244. (10.4161/cbt.3.2.775) / Molecular Cancer Therapy by S. Welsh (2004)
  76. Welsh, S. J., Bellamy, W. T., Briehl, M. M., & Powis, G. (2002). The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Research, 62, 5089–5095. / Cancer Research by S. J. Welsh (2002)
  77. Welsh, S. J., Williams, R. R., Birmingham, A., Newman, D. J., Kirkpatrick, D. L., & Powis, G. (2003). The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Molecular Cancer Therapy, 2, 235–243. / Molecular Cancer Therapy by S. J. Welsh (2003)
  78. Jones, D. T., & Harris, A. L. (2006). Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Molecular Cancer Therapy, 5, 2193–2202. (10.1158/1535-7163.MCT-05-0443) / Molecular Cancer Therapy by D. T. Jones (2006)
  79. Chau, N. M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., et al. (2005). Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Research, 65, 4918–4928. (10.1158/0008-5472.CAN-04-4453) / Cancer Research by N. M. Chau (2005)
  80. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., & Tarnawski, A. S. (2002). von Hippel Lindau tumor suppressor and HIF-1alpha: New targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB Journal, 16, 264–266. (10.1096/fj.01-0589fje) / FASEB Journal by M. K. Jones (2002)
  81. Palayoor, S. T., Tofilon, P. J., & Coleman, C. N. (2003). Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clinical Cancer Research, 9, 3150–3157. / Clinical Cancer Research by S. T. Palayoor (2003)
  82. Zhong, H., Willard, M., & Simons, J. (2004). NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: Multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. International Journal of Cancer, 112, 585–595. (10.1002/ijc.20438) / International Journal of Cancer by H. Zhong (2004)
  83. Knowles, H. J., Raval, R. R., Harris, A. L., & Ratcliffe, P. J. (2003). Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Research, 63, 1764–1768. / Cancer Research by H. J. Knowles (2003)
  84. Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T., Varesio, L., & Senderowicz, A. M. (1999). Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Research, 59, 5433–5437. / Cancer Research by G. Melillo (1999)
  85. Newcomb, E. W., Ali, M. A., Schnee, T., Lan, L., Lukyanov, Y., Fowkes, M., et al. (2005). Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: Implications for in vivo therapy. Journal of Neuro-Oncology, 7, 225–235. (10.1215/S1152851704000997) / Journal of Neuro-Oncology by E. W. Newcomb (2005)
  86. Buchler, P., Reber, H. A., Buchler, M. W., Friess, H., Lavey, R. S., & Hines, O. J. (2004). Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer, 100, 201–210. (10.1002/cncr.11873) / Cancer by P. Buchler (2004)
  87. Dervan, P. B., & Edelson, B. S. (2003). Recognition of the DNA minor groove by pyrrole-imidazole polyamides. Current Opinion in Structural Biology, 13, 284–299. (10.1016/S0959-440X(03)00081-2) / Current Opinion in Structural Biology by P. B. Dervan (2003)
  88. Olenyuk, B. Z., Zhang, G. J., Klco, J. M., Nickols, N. G., Kaelin, W. G., Jr., & Dervan, P. B. (2004). Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America, 101, 16768–16773. (10.1073/pnas.0407617101) / Proceedings of the National Academy of Sciences of the United States of America by B. Z. Olenyuk (2004)
  89. Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007). Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Research, 35(2), 363–370. (10.1093/nar/gkl1042) / Nucleic Acids Research by N. G. Nickols (2007)
  90. Van Dyke, M. M., & Dervan, P. B. (1984). Echinomycin binding sites on DNA. Science, 225, 1122–1127. (10.1126/science.6089341) / Science by M. M. Dyke Van (1984)
  91. Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., et al. (2005). Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Research, 65, 9047–9055. (10.1158/0008-5472.CAN-05-1235) / Cancer Research by D. Kong (2005)
  92. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., & Livingston, D. M. (2000). Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Medicine, 6, 1335–1340. (10.1038/82146) / Natural Medicines by A. L. Kung (2000)
  93. Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., et al. (2004). Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell, 6, 33–43. (10.1016/j.ccr.2004.06.009) / Cancer Cell by A. L. Kung (2004)
  94. Kaluz, S., Kaluzova, M., & Stanbridge, E. J. (2006). Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1alpha C-terminal activation domain. Molecular and Cellular Biology, 26, 5895–5907. (10.1128/MCB.00552-06) / Molecular and Cellular Biology by S. Kaluz (2006)
  95. Yeo, E. J., Ryu, J. H., Cho, Y. S., Chun, Y. S., Huang, L. E., Kim, M. S., et al. (2006). Amphotericin B blunts erythropoietin response to hypoxia by reinforcing FIH-mediated repression of HIF-1. Blood, 107, 916–923. (10.1182/blood-2005-06-2564) / Blood by E. J. Yeo (2006)
  96. Nagle, D. G., & Zhou, Y. D. (2006). Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Current Drugs Targets, 7, 355–369. (10.2174/138945006776054979) / Current Drugs Targets by D. G. Nagle (2006)
  97. Dai, J., Fishback, J. A., Zhou, Y. D., & Nagle, D. G. (2006). Sodwanone and Yardenone Triterpenes from a South African species of the marine sponge Axinella inhibit Hypoxia-Inducible Factor-1 (HIF-1) activation in both breast and prostate tumor cells. Journal of Natural Products, 69, 1715–1720. (10.1021/np060278q) / Journal of Natural Products by J. Dai (2006)
  98. Hodges, T. W., Hossain, C. F., Kim, Y. P., Zhou, Y. D., & Nagle, D. G. (2004). Molecular-targeted antitumor agents: The Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. Journal of Natural Products, 67, 767–771. (10.1021/np030514m) / Journal of Natural Products by T. W. Hodges (2004)
  99. Mohammed, K. A., Hossain, C. F., Zhang, L., Bruick, R. K., Zhou, Y. D., & Nagle, D. G. (2004). Laurenditerpenol, a new diterpene from the tropical marine alga Laurenciaintricata that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. Journal of Natural Products, 67, 2002–2007. (10.1021/np049753f) / Journal of Natural Products by K. A. Mohammed (2004)
  100. Zhou, Y. D., Kim, Y. P., Mohammed, K. A., Jones, D. K., Muhammad, I., Dunbar, D. C., et al. (2005). Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. Journal of Natural Products, 68, 947–950. (10.1021/np050029m) / Journal of Natural Products by Y. D. Zhou (2005)
  101. Choi, H., Chun, Y. S., Kim, S. W., Kim, M. S., & Park, J. W. (2006). Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: A mechanism of tumor growth inhibition. Molecular Pharmacology, 70, 1664–1671. (10.1124/mol.106.025817) / Molecular Pharmacology by H. Choi (2006)
  102. Lin, S., Tsai, S. C., Lee, C. C., Wang, B. W., Liou, J. Y., & Shyu, K. G. (2004). Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Molecular Pharmacology, 66, 612–619. (10.1016/S0026-895X(24)05644-X) / Molecular Pharmacology by S. Lin (2004)
  103. Li, M. H., Miao, Z. H., Tan, W. F., Yue, J. M., Zhang, C., Lin, L. P., et al. (2004). Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation. Clinical Cancer Research, 10, 8266–8274. (10.1158/1078-0432.CCR-04-0951) / Clinical Cancer Research by M. H. Li (2004)
  104. Cai, X. F., Jin, X., Lee, D., Yang, Y. T., Lee, K., Hong, Y. S., et al. (2006). Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit Hypoxia-Inducible Factor-1 in AGS human gastric cancer cells. Journal of Natural Products, 69, 1095–1097. (10.1021/np060081y) / Journal of Natural Products by X. F. Cai (2006)
  105. Hasebe, Y., Egawa, K., Yamazaki, Y., Kunimoto, S., Hirai, Y., Ida, Y., et al. (2003). Specific inhibition of hypoxia-Inducible Factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids. Biological & Pharmaceutical Bulletin, 26, 1379–1383. (10.1248/bpb.26.1379) / Biological & Pharmaceutical Bulletin by Y. Hasebe (2003)
  106. Li, L., Lin, X., Shoemaker, A. R., Albert, D. H., Fesik, S. W., & Shen, Y. (2006). Hypoxia-Inducible Factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clinical Cancer Research, 12, 4747–4754. (10.1158/1078-0432.CCR-05-2842) / Clinical Cancer Research by L. Li (2006)
  107. Brown, L. M., Cowen, R. L., Debray, C., Eustace, A., Erler, J. T., Sheppard, F. C., et al. (2005). Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting Hypoxia Inducible Factor. Molecular Pharmacology, 69, 411–418. (10.1124/mol.105.015743) / Molecular pharmacology by L. M. Brown (2005)
  108. Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell, 5, 429–441. (10.1016/S1535-6108(04)00115-1) / Cancer Cell by B. J. Moeller (2004)
  109. Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., et al. (2005). Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 8, 99–110. (10.1016/j.ccr.2005.06.016) / Cancer Cell by B. J. Moeller (2005)
  110. Mie, L. Y., Kim, S. H., Kim, H. S., Jin, S. M., Nakajima, H., Jeong, K. H., et al. (2003). Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochemical and Biophysical Research Communications, 300, 241–246. (10.1016/S0006-291X(02)02787-0) / Biochemical and Biophysical Research Communications by L. Y. Mie (2003)
  111. Jones, D. T., Pugh, C. W., Wigfield, S., Stevens, M. F. G., & Harris, A. L. (2006). Novel thioredoxin inhibitors paradoxically increase Hypoxia-Inducible Factor-{alpha} expression but decrease functional transcriptional activity, DNA binding, and degradation. Clinical Cancer Research, 12, 5384–5394. (10.1158/1078-0432.CCR-05-2380) / Clinical Cancer Research by D. T. Jones (2006)
Dates
Type When
Created 18 years, 4 months ago (April 5, 2007, 11:45 a.m.)
Deposited 7 months, 2 weeks ago (Jan. 15, 2025, 9:39 a.m.)
Indexed 1 week, 2 days ago (Aug. 20, 2025, 9:01 a.m.)
Issued 18 years, 4 months ago (April 6, 2007)
Published 18 years, 4 months ago (April 6, 2007)
Published Online 18 years, 4 months ago (April 6, 2007)
Published Print 18 years, 1 month ago (July 24, 2007)
Funders 0

None

@article{Melillo_2007, title={Targeting hypoxia cell signaling for cancer therapy}, volume={26}, ISSN={1573-7233}, url={http://dx.doi.org/10.1007/s10555-007-9059-x}, DOI={10.1007/s10555-007-9059-x}, number={2}, journal={Cancer and Metastasis Reviews}, publisher={Springer Science and Business Media LLC}, author={Melillo, Giovanni}, year={2007}, month=apr, pages={341–352} }